Role of raloxifene in the management of postmenopausal osteoporosis of rheumatoid arthritis patients

[1] Doran, M.F., et al., Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis & Rheumatism, 2002. 46(3): p. 625–631. DoranM.F. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period Arthritis & Rheumatism 2002 46 3 625 631 Search in Google Scholar

[2] Goemaere, S., et al., Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. The Journal of rheumatology, 1990. 17(12): p. 1620–1622. GoemaereS. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition The Journal of rheumatology 1990 17 12 1620 1622 Search in Google Scholar

[3] d’Elia, H.F., et al., Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Annals of the rheumatic diseases, 2003. 62(7): p. 617–623. d’EliaH.F. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis Annals of the rheumatic diseases 2003 62 7 617 623 Search in Google Scholar

[4] Anderson, G.L., et al., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. 2004. AndersonG.L. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial 2004 Search in Google Scholar

[5] Investigators, W.G.f.t.W.s.H.I., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Jama, 2002. 288(3): p. 321–333. Investigators, W.G.f.t.W.s.H.I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial Jama 2002 288 3 321 333 Search in Google Scholar

[6] D’Elia, H.F., et al., Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. The Journal of rheumatology, 2003. 30(7): p. 1456–1463. D’EliaH.F. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis The Journal of rheumatology 2003 30 7 1456 1463 Search in Google Scholar

[7] Jochems, C., et al., Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 2007. 56(10): p. 3261–3270. JochemsC. Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 2007 56 10 3261 3270 Search in Google Scholar

[8] Lafage-Proust, M.H., B. Boudignon, and T. Thomas, Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments. Joint Bone Spine, 2003. 70(2): p. 109–118. Lafage-ProustM.H. BoudignonB. ThomasT. Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments Joint Bone Spine 2003 70 2 109 118 Search in Google Scholar

[9] Straub, R.H., The complex role of estrogens in inflammation. Endocrine reviews, 2007. 28(5): p. 521–574. StraubR.H. The complex role of estrogens in inflammation Endocrine reviews 2007 28 5 521 574 Search in Google Scholar

[10] Deroo, B.J. and K.S. Korach, Estrogen receptors and human disease. The Journal of clinical investigation, 2006. 116(3): p. 561–570. DerooB.J. KorachK.S. Estrogen receptors and human disease The Journal of clinical investigation 2006 116 3 561 570 Search in Google Scholar

[11] Fabian, C.J. and B.F. Kimler, Selective estrogen-receptor modulators for primary prevention of breast cancer. Journal of Clinical Oncology, 2005. 23(8): p. 1644–1655. FabianC.J. KimlerB.F. Selective estrogen-receptor modulators for primary prevention of breast cancer Journal of Clinical Oncology 2005 23 8 1644 1655 Search in Google Scholar

[12] Temin, S., American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Gynecologic oncology, 2009. 115(1): p. 132–134. TeminS. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction Gynecologic oncology 2009 115 1 132 134 Search in Google Scholar

[13] Stefanick, M.L., Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. The American journal of medicine, 2005. 118(12): p. 64–73. StefanickM.L. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration The American journal of medicine 2005 118 12 64 73 Search in Google Scholar

[14] Jochems, C., et al., Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis. Clinical & Experimental Immunology, 2008. 152(3): p. 593–597. JochemsC. Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis Clinical & Experimental Immunology 2008 152 3 593 597 Search in Google Scholar

[15] Green, S. and J. Higgins, Cochrane handbook for systematic reviews of interventions. 2005, Version. GreenS. HigginsJ. Cochrane handbook for systematic reviews of interventions 2005 Version. Search in Google Scholar

[16] Higgins, J., Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org, 2011. HigginsJ. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011] The Cochrane Collaboration www.cochrane-handbook.org, 2011 Search in Google Scholar

[17] Lee, W., et al., SAT0497 Effect of Raloxifene on Osteoporosis and Disease Activity in Postmenopausal Female with Rheumatic Diseases. Annals of the Rheumatic Diseases, 2014. 73(Suppl 2): p. 772–772. LeeW. SAT0497 Effect of Raloxifene on Osteoporosis and Disease Activity in Postmenopausal Female with Rheumatic Diseases Annals of the Rheumatic Diseases 2014 73 Suppl 2 772 772 Search in Google Scholar

[18] Mok, C.C., et al., Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Annals of the rheumatic diseases, 2011. 70(5): p. 778–784. MokC.C. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial Annals of the rheumatic diseases 2011 70 5 778 784 Search in Google Scholar

[19] Stoica, S. and G. Zugravu, THU0402 Effects of Raloxifene for Prevention of Bone Loss in Rheumatoid Arthritis Women Receiving Long-Term Glucocorticoids. Annals of the Rheumatic Diseases, 2013. 72(Suppl 3): p. A301–A301. StoicaS. ZugravuG. THU0402 Effects of Raloxifene for Prevention of Bone Loss in Rheumatoid Arthritis Women Receiving Long-Term Glucocorticoids Annals of the Rheumatic Diseases 2013 72 Suppl 3 A301 A301 Search in Google Scholar

[20] Mokuda, S., et al., Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels. Journal of endocrinological investigation, 2012. 35(7): p. 661–664. MokudaS. Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels Journal of endocrinological investigation 2012 35 7 661 664 Search in Google Scholar

[21] Guiducci, S., et al., Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis. Arthritis research & therapy, 2005. 7(6): p. R1244. GuiducciS. Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis Arthritis research & therapy 2005 7 6 R1244 Search in Google Scholar

[22] Woolf, A.D., An update on glucocorticoid-induced osteoporosis. Current opinion in rheumatology, 2007. 19(4): p. 370–375. WoolfA.D. An update on glucocorticoid-induced osteoporosis Current opinion in rheumatology 2007 19 4 370 375 Search in Google Scholar

[23] Angeli, A., et al., High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone, 2006. 39(2): p. 253–259. AngeliA. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study Bone 2006 39 2 253 259 Search in Google Scholar

[24] Van Staa, T., et al., Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology, 2000. 39(12): p. 1383–1389. Van StaaT. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses Rheumatology 2000 39 12 1383 1389 Search in Google Scholar

[25] De Vries, F., et al., Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case–control study. Journal of internal medicine, 2007. 261(2): p. 170–177. De VriesF. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case–control study Journal of internal medicine 2007 261 2 170 177 Search in Google Scholar

[26] Ozmen, B., et al., Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw, 2007. 18(3): p. 148–153. OzmenB. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis Eur Cytokine Netw 2007 18 3 148 153 Search in Google Scholar

[27] Ettinger, B., et al., Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Jama, 1999. 282(7): p. 637–645. EttingerB. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Jama 1999 282 7 637 645 Search in Google Scholar

[28] Adomaityte, J., M. Farooq, and R. Qayyum, Effect of raloxifene therapy on venous thromboembolism in postmenopausal women: a meta-analysis. Thrombosis and haemostasis, 2008. 99(02): p. 338–342. AdomaityteJ. FarooqM. QayyumR. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women: a meta-analysis Thrombosis and haemostasis 2008 99 02 338 342 Search in Google Scholar

[29] Islander, U., et al., Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis. Arthritis research & therapy, 2011. 13(3): p. R96. IslanderU. Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis Arthritis research & therapy 2011 13 3 R96 Search in Google Scholar

[30] Taranta, A., et al., The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone, 2002. 30(2): p. 368–376. TarantaA. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro Bone 2002 30 2 368 376 Search in Google Scholar

[31] Delmas, P.D., et al., Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New England Journal of Medicine, 1997. 337(23): p. 1641–1647. DelmasP.D. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women New England Journal of Medicine 1997 337 23 1641 1647 Search in Google Scholar

[32] Jochems, C., et al., Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation. Arthritis research & therapy, 2005. 7(4): p. R837. JochemsC. Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation Arthritis research & therapy 2005 7 4 R837 Search in Google Scholar

[33] Holmdahl, R., L. Jansson, and M. Andersson, Female sex hormones suppress development of collagen-induced arthritis in mice. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 1986. 29(12): p. 1501–1509. HolmdahlR. JanssonL. AnderssonM. Female sex hormones suppress development of collagen-induced arthritis in mice Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 1986 29 12 1501 1509 Search in Google Scholar

[34] Yamasaki, D., et al., Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. Bone, 2001. 28(6): p. 634–640. YamasakiD. Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis Bone 2001 28 6 634 640 Search in Google Scholar

[35] Miller, P. and R. Derman, What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporosis international, 2010. 21(11): p. 1793–1802. MillerP. DermanR. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporosis international 2010 21 11 1793 1802 Search in Google Scholar

[36] Miller, P.D., et al., Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. Journal of bone and mineral research, 2008. 23(4): p. 525–535. MillerP.D. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study Journal of bone and mineral research 2008 23 4 525 535 Search in Google Scholar

[37] Silverman, S.L., et al., Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. Journal of bone and mineral research, 2008. 23(12): p. 1923–1934. SilvermanS.L. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial Journal of bone and mineral research 2008 23 12 1923 1934 Search in Google Scholar

[38] Moxley, G., et al., Sexual dimorphism in innate immunity. Arthritis & Rheumatism, 2002. 46(1): p. 250–258. MoxleyG. Sexual dimorphism in innate immunity Arthritis & Rheumatism 2002 46 1 250 258 Search in Google Scholar

[39] Erlandsson, M., et al., Oestrogen receptor specificity in oestradiol-mediated effects on B lymphopoiesis and immunoglobulin production in male mice. Immunology, 2003. 108(3): p. 346–351. ErlandssonM. Oestrogen receptor specificity in oestradiol-mediated effects on B lymphopoiesis and immunoglobulin production in male mice Immunology 2003 108 3 346 351 Search in Google Scholar

[40] Messalli, E.M., et al., Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas, 2007. 56(1): p. 38–44. MessalliE.M. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women Maturitas 2007 56 1 38 44 Search in Google Scholar

[41] Cutolo, M., et al., Sex hormones and rheumatoid arthritis. Autoimmunity reviews, 2002. 1(5): p. 284–289. CutoloM. Sex hormones and rheumatoid arthritis Autoimmunity reviews 2002 1 5 284 289 Search in Google Scholar

[42] Cutolo, M., et al., The role of androgens in rheumatic diseases. The Israel Medical Association journal: IMAJ, 2001. 3(10): p. 743. CutoloM. The role of androgens in rheumatic diseases The Israel Medical Association journal: IMAJ 2001 3 10 743 Search in Google Scholar

[43] Cutolo, M., et al., Androgen and estrogen receptors are present in primary cultures of human synovial macrophages. The Journal of Clinical Endocrinology & Metabolism, 1996. 81(2): p. 820–827. CutoloM. Androgen and estrogen receptors are present in primary cultures of human synovial macrophages The Journal of Clinical Endocrinology & Metabolism 1996 81 2 820 827 Search in Google Scholar

[44] Ushiyama, T., et al., Association of oestrogen receptor gene polymorphisms with age at onset of rheumatoid arthritis. Annals of the rheumatic diseases, 1999. 58(1): p. 7–10. UshiyamaT. Association of oestrogen receptor gene polymorphisms with age at onset of rheumatoid arthritis Annals of the rheumatic diseases 1999 58 1 7 10 Search in Google Scholar

[45] Cutolo, M., et al., Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Annals of the New York Academy of Sciences, 2002. 966(1): p. 131–142. CutoloM. Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis Annals of the New York Academy of Sciences 2002 966 1 131 142 Search in Google Scholar

[46] Cutolo, M., et al., Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis. Annals of the New York Academy of Sciences, 2003. 992(1): p. 107–117. CutoloM. Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis Annals of the New York Academy of Sciences 2003 992 1 107 117 Search in Google Scholar

[47] Walsh, B.W., et al., Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. Jama, 1998. 279(18): p. 1445–1451. WalshB.W. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women Jama 1998 279 18 1445 1451 Search in Google Scholar

[48] Khalkhali-Ellis, Z., et al., Estrogen and progesterone regulation of human fibroblast-like synoviocyte function in vitro: implications in rheumatoid arthritis. The Journal of rheumatology, 2000. 27(7): p. 1622–1631. Khalkhali-EllisZ. Estrogen and progesterone regulation of human fibroblast-like synoviocyte function in vitro: implications in rheumatoid arthritis The Journal of rheumatology 2000 27 7 1622 1631 Search in Google Scholar

[49] Fuleihan, G.E.-H., Tissue-specific estrogens—the promise for the future. 1997, Mass Medical Soc. FuleihanG.E.-H. Tissue-specific estrogens—the promise for the future 1997 Mass Medical Soc. Search in Google Scholar

[50] Levenson, A.S., et al., Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. Cancer letters, 1998. 125(1–2): p. 215–220. LevensonA.S. Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells Cancer letters 1998 125 1–2 215 220 Search in Google Scholar

[51] Huber, C., et al., Selective estrogen receptor modulator inhibits osteocyte apoptosis during abrupt estrogen withdrawal: implications for bone quality maintenance. Calcified tissue international, 2007. 81(2): p. 139–144. HuberC. Selective estrogen receptor modulator inhibits osteocyte apoptosis during abrupt estrogen withdrawal: implications for bone quality maintenance Calcified tissue international 2007 81 2 139 144 Search in Google Scholar

[52] Islander, U., et al., Estrogens in rheumatoid arthritis; the immune system and bone. Molecular and cellular endocrinology, 2011. 335(1): p. 14–29. IslanderU. Estrogens in rheumatoid arthritis; the immune system and bone Molecular and cellular endocrinology 2011 335 1 14 29 Search in Google Scholar

[53] Phillips, K., A. Aliprantis, and J. Coblyn, Strategies for the prevention and treatment of osteoporosis in patients with rheumatoid arthritis. Drugs & aging, 2006. 23(10): p. 773–779. PhillipsK. AliprantisA. CoblynJ. Strategies for the prevention and treatment of osteoporosis in patients with rheumatoid arthritis Drugs & aging 2006 23 10 773 779 Search in Google Scholar

[54] Foster, S.A., et al., Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. BMC women's health, 2008. 8(1): p. 24. FosterS.A. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates BMC women's health 2008 8 1 24 Search in Google Scholar

[55] Kung, A.W., et al., Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women. The Journal of Clinical Endocrinology & Metabolism, 2003. 88(7): p. 3130–3136. KungA.W. Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women The Journal of Clinical Endocrinology & Metabolism 2003 88 7 3130 3136 Search in Google Scholar